Yahoo Finance5h
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
WILMINGTON, Del., November 18, 2024--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that it will pause enrollment in ...
Yahoo Finance6h
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their resubmitted supplemental biologics license ...
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma
Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...
Pharmabiz16h
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...